跳至主要内容
临床试验/EUCTR2020-005412-21-BE
EUCTR2020-005412-21-BE进行中(未招募)1 期

Effect of dobutamine on hepatic blood flow during goal-directed hemodynamic therapy.

Z Gent0 个研究点目标入组 70 人开始时间: 2021年2月23日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Adult = 18 years = 80 years (female or male).
  • ASA I – II – III.
  • Able to comprehend, sign and date the written informed consent document to participate in the clinical trial.
  • Patient is scheduled for pancreaticoduodenectomy (Whipple`s procedure).
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 25
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 45

排除标准

  • Allergy to the medication dobutamine.
  • Renal insufficiency (SCr > 2 mg/dL).
  • Severe heart failure (EF < 25%).
  • Hemodynamic unstable patients.
  • Atrial fibrillation.
  • Sinustachycardia > 100 bpm on pre-operative electrocardiogram.
  • BMI > 40.
  • Severe coagulopathy (INR > 2).
  • Thrombocytopenia (< 80 x 103 /mcL).
  • End stage liver disease and/or portal hypertension.
  • Pregnancy and breastfeeding women.

研究者

发起方
Z Gent

相似试验